Volitionrx Limited

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

VolitionRx reports 240% revenue growth, eyes expansion in veterinary diagnostics

VolitionRx reported strong revenue growth in 2022 but faced a net loss due to higher costs, emphasizing the need for cost management.
The company's focus on commercializing its Nu.Q platform and expanding into veterinary diagnostics presents growth opportunities.
While challenges like increased expenditures and competition exist, VolitionRx's strategic partnerships and product pipeline position it for future success.
Exploring new applications of NETosis technology in animal health and upcoming investor events highlight potential growth avenues for VolitionRx.

VolitionRx reports robust Q1 results, eyes growth in cancer testing

VolitionRx Limited's Q1 2023 performance reflects strong financials, strategic partnerships, and promising revenue from innovative cancer testing products.
The company's strengths include financial stability, strategic collaborations, and growth potential in the veterinary and cancer testing markets.
Challenges in managing expenses, sustaining revenue growth, and strategic focus require careful navigation for continued success.
Opportunities abound in leveraging partnerships, exploring new markets, and proactive initiatives for future growth and market expansion.

VolitionRx reports robust Q2 earnings, poised for growth in cancer diagnostics

VolitionRx Limited delivered a strong performance in Q2 2023, marked by significant revenue growth and a solid financial position, underpinned by cash reserves and milestone payments.
The company's focus on advancing Nu.Q technology, expanding partnerships, and making progress in cancer research bodes well for future growth and innovation.
While facing challenges in scaling sales efforts and managing R&D expenses, VolitionRx has opportunities to drive revenue growth through strategic partnerships and market expansion.

VolitionRx reports robust revenue growth and global expansion opportunities

VolitionRx Limited's Q3 2023 performance showcased strong revenue growth and global expansion in Nu.Q Vet Cancer Test sales.
While facing challenges in regulatory timelines and funding, the company's strategic strengths lie in its innovative products and prudent financial approach.
Opportunities in new product launches, market education, and global expansion position VolitionRx for continued growth and breakthroughs in cancer detection.

VolitionRx reports stellar revenue growth, eyes global expansion with strategic partnerships

VolitionRx Limited's Q4 2023 earnings call highlighted robust revenue growth, strong cash position, and strategic partnerships driving expansion. While facing challenges in financing and operational efficiency, the company's focus on innovative technologies and global market penetration positions it well for future growth and partnerships.

Volitionrx reports revenue growth and eyes cash flow positivity by 2025

Volitionrx Limited (VNRX) is on track for growth with strong revenue performance, successful product launches, and a focus on achieving cash flow positivity. The company faces challenges in expense control and funding strategies but has opportunities in upcoming data releases and licensing deals.

Volitionrx reports robust Q3 revenue growth and strategic advancements

Volitionrx Limited demonstrated strong performance in revenue growth, innovation, and financial progress.
Key strengths include successful product sales, research advancements, and strategic financial planning.
Challenges in market dynamics and cost management require strategic focus and operational efficiency improvements.
Opportunities for growth exist in market expansion, cost optimization, new partnerships, and research publications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00am U.S. Eastern Time ·        Executed global licensing and supply agreement with Heska Corporation to distribute Nu.Q® Vet Cancer Screening Test at the Point of Care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones. Under said agreement will receive ongoing additional revenue for key components and kits.

VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update

Heska

VolitionRx (NYSE-A:VNRX) Ltd has struck an exclusive $28 million deal with veterinary diagnostic firm Heska Corporation to license and sell the former's Nu.Q vet cancer screening test at the point-of-care for pets. Heska will receive the worldwide rights to sell the test while VolitionRx (NYSE-A:VNRX) will get a $10 million upfront payment on signing and up to $18 million based upon near to mid-term milestones.

VolitionRx strikes exclusive $28M deal with Heska Corp to sell its Nu.Q vet cancer screening test

AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) ("Heska") to sell its Nu.Q® Vet Cancer Screening Test at the point of care for companion animals. Heska is a leading global provider of advanced veterinary diagnostics.

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care

LOVELAND, Colo. , March 29, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, has announced an exclusive global supply and licensing agreement with VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") to adapt and commercialize the Nu.Q® Vet Cancer Screening Test at the point of care for companion animals on Heska's technology.

Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Cancer Screen

Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday March 31, 08.00a.m.

VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the company's Nu.Q® assays, when used in conjunction with the Fecal Immunochemical Test (FIT), can detect colorectal cancer and all high-risk advanced adenomas in symptomatic patients, and thereby reduce unnecessary colonoscopies. The studies also demonstrated that the company's Nu.Q® assays can improve the detection of high-risk adenomas in asymptomatic patients.

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

VolitionRX develops and sells a simple and cost effective blood test to detect cancers and other serious diseases in our best friends, dogs.

VolitionRX: Cancer Diagnostic Tool For Our Best Friends

SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs in Singapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with SAGE Healthcare into centralized labs in other key Asian markets. Volition's global strategy is to implement similar agreements with multiple companies to ensure the broadest possible accessibility to the Nu.Q® Test worldwide.

Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time Healthy balance sheet with approximately $22.9 million in cash and cash equivalents In advanced term sheet negotiations with three large multi-national veterinary companies on potential worldwide licensing/distribution arrangements Expanded the Company's intellectual property portfolio Made significant progress with the Company's Nu.Q® NETs development Continued focus on, and made strong progress towards additional new product launches and licensing in both the human and veterinary spaces worldwide AUSTIN, TX, Nov. 10, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2021.

VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update

AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in addition to providing a business update.

VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update

Positive data show Nu.Q® can be used to monitor for disease response and progression including remission monitoring in cancer bearing dogs. Paves the way for second Nu.Q® Vet product launch planned for 2022.

Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference

Strong balance sheet with approximately $27.9 million in cash and cash equivalents Strengthened the Company's veterinary leadership team to drive commercial focus Expanded the Company's intellectual property portfolio Published two clinical papers Continued focus on, and made strong progress towards, product launches and licensing in both the human and veterinary spaces worldwide AUSTIN, Texas, Aug. 11, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2021. Volition management will host a conference call tomorrow, August 12 at 8:00 a.m.

VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update

AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, August 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2021, in addition to providing a business update.

VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with researchers at two leading  NHS Foundation Trusts on two studies in COVID-19 for which abstracts were released this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2021. Dr. Jake Micallef, Chief Scientific Officer of Volition said "We believe our Nu.Q® NETs assay will have wide applicability for monitoring diseases with a NETs component (such as COVID-19, sepsis, autoimmune diseases and cancer) and potentially to risk stratify patients for treatment selection.

Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring

Secured strongest-ever balance sheet with approximately $33.1 million in cash Strengthened the Company's leadership team to drive commercial focus Expanded the Company's intellectual property portfolio Initiated production of product components at scale at the Company's Silver One facility Published three clinical papers Continued focus on product launches and licensing in both the human and veterinary spaces AUSTIN, Texas, May 11, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2021. Volition management will host a conference call tomorrow, May 12 at 8:00 a.m.

VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday May 12, at 8:00 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2021, in addition to providing a business update.

VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the publication in Scientific Reports of a paper entitled " A Novel Proteomics Approach to Epigenetic Profiling of Circulating Nucleosomes ". Dr. Marielle Herzog, lead author of the paper and Volition's Research and Development Director, commented, "Our novel method detects and quantifies histone modifications present in the circulating nucleosomes in the blood of cancer patients.

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment, effective May 1, 2021, of Dr. Tom Butera DVM, to the position of Chief Executive Officer, Volition Veterinary Diagnostics Development LLC, assuming such role from Dr. Gaetan Michel who continues to serve as Chief Operating Officer of Volition and Chief Executive Officer of Belgian Volition. "We are delighted that Tom has agreed to lead our Veterinary subsidiary.

VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Ms. Kim Nguyen and Mr.

VolitionRx Limited Appoints Two New Directors

Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial for Non-Hodgkin's Lymphoma Expanded research program for the use of Nu.Q® technology in NETosis (COVID-19 and sepsis) Strengthened intellectual property portfolio Purchased and opened first production facility Strongest-ever cash position following a public offering in February 2021 AUSTIN, Texas, March 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year ended December 31, 2020. Volition management will host a conference call tomorrow, March 23 at 8:00 a.m.

VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update

AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with Swiss-based Santersus AG, a private company that has an abstract released today at the International Society for Apheresis meeting (e-ISFA), which is being held virtually this year. The poster presentation entitled "Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis" given by Dr. Andrew Aswani, Consultant in Intensive Care Medicine & Anesthesia at a leading London Hospital and Chief Medical Officer of Santersus AG, includes data showing that Nu.Q® is an effective method for monitoring Santersus' highly selective plasmapheresis treatment targeting Neutrophil Extracellular Traps ("NETs") in sepsis.

New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis

AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to discuss its financial and operating results for the full fiscal year 2020, in addition to providing a business update.

VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update

AUSTIN, Texas, March 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at six conferences in March...

VolitionRx Limited to Present at Conferences in March 2021

Volition is one of the sponsors for the upcoming Benzinga Global Small Cap Conference set to take place on December 8-9, 2020. Given the growing population, it is expected that the number of cancer diagnoses will continue to increase.

Volition Has Released A Screening Test To Help Detect Early Stages Of Cancer In Dogs

VolitionRx began commercial sales of a blood test for pet cancer. There is no other product available on the market for testing cancer in dogs despite cancer being the leading cause of death for dogs over ten years old.

News for Volitionrx Limited Stock (VNRX)